电疗法改善了莱维体痴呆症患者的耐治疗抑郁症

相关实验视频

Updated: May 14, 2025

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.9K

Yavuz Sultan Selim Akgul¹, Murat Gultekin², Saliha Demirel Ozsoy³

¹Division of Geriatrics, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.

Neurocase

|April 12, 2025

概括

莱维体痴呆症 (LBD) 通常伴有严重的抑郁症. 电疗法 (ECT) 有效地改善了LBD患者的抑郁症状,在药物失效时提供了一个重要的治疗选择.

科学领域:

神经学神经学
老年病的医生老年病的医生
精神病学是一个精神病学.

背景情况:

莱维体痴呆症 (LBD) 是第二常见的神经退行性痴呆症,经常伴有抑郁症和焦虑症等神经精神病症状.
这些症状可能是认知能力下降的先兆,导致误诊和低于最佳的治疗策略.
在LBD中,神经精神病症状带来了重大的诊断和治疗挑战.

研究的目的:

要突出诊断和治疗莱维体痴呆症神经精神病症状的挑战.
提出电疗法 (ECT) 作为一种潜在的治疗方法,用于严重的,治疗耐药的抑郁症在LBD.
强调LBD早期识别在晚发性抑郁症中的重要性,以提供量身定制的治疗.

主要方法:

一个68岁的女性患者的病例报告,诊断出患有莱维体痴呆症.
该患者接受了多次电疗法 (ECT) 治疗,以治疗持续严重的抑郁症和自杀念头.
在医院住院期间和之后对ECT治疗的症状反应的临床观察.

主要成果:

电疗法 (ECT) 在LBD患者中显著改善了抑郁症状和自杀念头.
在多次住院期间观察到有症状的益处,这表明持续的疗效.
这一案例证明了ECT在管理LBD中耐药性严重抑郁症的潜力.

结论:

电疗法 (ECT) 是一个可行的和有效的治疗选择,用于严重抑郁症的患者,莱维体痴呆症.
在患有晚期抑郁症的患者中,早期和准确的LBD诊断对于适当的管理至关重要.
这一案例支持在药物治疗对LBD神经精神疾病症状不足时考虑ECT.

关键词:

抑郁症抑郁症抑郁症莱维体痴呆症 (Lewy体痴呆症) 是一种疾病.痴呆症痴呆症是一种痴呆症.电疗法是一种电疗法.治疗耐药性抑郁症治疗耐药性抑郁症

相关概念视频

01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

01:24

Parkinson's Disease: Treatment

158

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

158

01:22

Alzheimer's Disease: Treatment

132

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

132

01:23

Antidepressant Drugs: MAOIs and Other Agents

165

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

165